“Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer” has been added to your cart. View cart

Article: ANTI-PF4/POLYANION ANTIBODY INDUCED AUTOIMMUNE HIT: A NEW MECHANISM OF AUTOIMMUNITY

€3.03

SKU: product-article-23699 Category: General

Description
Reviews (0)

Description

ANTI-PF4/POLYANION ANTIBODY INDUCED AUTOIMMUNE HIT: A NEW MECHANISM OF AUTOIMMUNITY

Reviews

There are no reviews yet.

Be the first to review “Article: ANTI-PF4/POLYANION ANTIBODY INDUCED AUTOIMMUNE HIT: A NEW MECHANISM OF AUTOIMMUNITY”

You must be logged in to post a review.

Top

Article: ANTI-PF4/POLYANION ANTIBODY INDUCED AUTOIMMUNE HIT: A NEW MECHANISM OF AUTOIMMUNITY

Description

Reviews

Related products

Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer

Article: INTRODUCTION

Article: Highlights in squamous cell carcinoma of the head and neck

Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma